Pharmaceutical raw material CAS 89778-27-8 Toremifene Citrate Fareston

• Product Name Pharmaceutical raw material CAS 89778-27-8 Toremifene Citrate Fareston
  CAS No.89778-27-8
  Purity99%
  Min QuantityKilograms
  Price0.1~10
• View Contact Detail

• 
  Molecular Structure

Detailed Description

CAS 89778-27-8 Toremifene Citrate Fareston


Product Name:Toremifene Citrate
Synonyms:Fareston
CAS Registry Number:89778-27-8
Assay: 99%
Molecular Formula: C26H28ClNO.C6H8O7
Molecular Weight: 598.09
Melting Point: 158-164 oC
Boiling Point: 535.1 oC at 760 mmHg
Density: 1.045g/cm3
Refractive index: 1,416-1,418
Appearance: White or almost white powder

Toremifene Citrate Effect

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

It has already been covered that Toremifene is a SERM, and serves to block Estrogen at various receptor sites in certain tissues within the body (breast tissue in particular). As a layman explanation, Toremifene pretends to be a ‘fake’ Estrogen that occupies Estrogen receptors within breast tissue. With these receptors occupied by Toremifene, real Estrogen cannot perform their jobs there. Toremifene does not reduce total blood plasma levels of Estrogen. In addition to being antagonistic to Estrogen receptors in breast tissue, it is also antagonistic to Estrogen at the hypothalamus gland (this essentially ‘tricks’ the hypothalamus into thinking there is little or no circulating Estrogen levels in the body, causing it to increase its manufacture of Testosterone so that it can utilize aromatization to restore these levels.

Toremifene Citrate exerts its effects by antagonizing the estrogen receptor in some tissues, and agonizing it in others. In this way, certain estrogenic pathways are activated and others are blockaded. It seems to exert estrogenic effects on blood lipids, reducing LDL and total cholesterol, as well as estrogenic effects on bone, improving density. It would also appear to exert anti-estrogenic effects in breast tissue, displacing the traditional effects of estrogen, effectively helping prevent breast cancer in postmenopausal women.

• 
• Pharmaceutical raw material CAS 89778-27-8 Toremifene Citrate Fareston